Negin Holland
Overview
Explore the profile of Negin Holland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hughes L, Adams N, Rouse M, Naessens M, Shaw A, Murley A, et al.
Alzheimers Dement
. 2025 Feb;
:e14531.
PMID: 39968697
Introduction: We examined how abnormal prefrontal neurophysiology and changes in gamma-aminobutyric acid-ergic (GABAergic) neurotransmission contribute to behavioral impairments in disorders associated with frontotemporal lobar degeneration (FTLD). Methods: We recorded magnetoencephalography...
2.
Orlando I, Hezemans F, Ye R, Murley A, Holland N, Regenthal R, et al.
Brain Commun
. 2024 Oct;
6(5):fcae297.
PMID: 39464213
Noradrenaline is a powerful modulator of cognitive processes, including action decisions underlying saccadic control. Changes in saccadic eye movements are common across neurodegenerative diseases of ageing, including Parkinson's disease. With...
3.
Holland N, Savulich G, Jones P, Whiteside D, Street D, Swann P, et al.
Mov Disord
. 2024 Apr;
39(7):1166-1178.
PMID: 38671545
Background/objective: The corticobasal syndrome (CBS) is a complex asymmetric movement disorder, with cognitive impairment. Although commonly associated with the primary 4-repeat-tauopathy of corticobasal degeneration, clinicopathological correlation is poor, and a...
4.
Whiteside D, Holland N, Tsvetanov K, Mak E, Malpetti M, Savulich G, et al.
Nat Commun
. 2023 Dec;
14(1):8458.
PMID: 38114493
There is extensive synaptic loss from frontotemporal lobar degeneration, in preclinical models and human in vivo and post mortem studies. Understanding the consequences of synaptic loss for network function is...
5.
Ye R, Hezemans F, OCallaghan C, Tsvetanov K, Rua C, Jones P, et al.
J Neurosci
. 2023 Sep;
43(42):7028-7040.
PMID: 37669861
Parkinson's disease (PD) and progressive supranuclear palsy (PSP) both impair response inhibition, exacerbating impulsivity. Inhibitory control deficits vary across individuals and are linked with worse prognosis, and lack improvement on...
6.
Williams R, Adams N, Hughes L, Rouse M, Murley A, Naessens M, et al.
Sci Rep
. 2023 Jun;
13(1):8939.
PMID: 37268659
Self-report scales are widely used in cognitive neuroscience and psychology. However, they rest on the central assumption that respondents engage meaningfully. We hypothesise that this assumption does not hold for...
7.
Holland N, Jones P, Savulich G, Naessens M, Malpetti M, Whiteside D, et al.
Mov Disord
. 2023 May;
38(7):1316-1326.
PMID: 37171832
Background: Synaptic loss is characteristic of many neurodegenerative diseases; it occurs early and is strongly related to functional deficits. Objective: In this longitudinal observational study, we determine the rate at...
8.
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials
Street D, Jabbari E, Costantini A, Jones P, Holland N, Rittman T, et al.
Brain
. 2023 Mar;
146(8):3232-3242.
PMID: 36975168
The advent of clinical trials of disease-modifying agents for neurodegenerative disease highlights the need for evidence-based end point selection. Here we report the longitudinal PROSPECT-M-UK study of progressive supranuclear palsy...
9.
Adams N, Jafarian A, Perry A, Rouse M, Shaw A, Murley A, et al.
Brain
. 2022 Dec;
146(6):2584-2594.
PMID: 36514918
Synaptic loss occurs early in many neurodegenerative diseases and contributes to cognitive impairment even in the absence of gross atrophy. Currently, for human disease there are few formal models to...
10.
Malpetti M, Jones P, Cope T, Holland N, Naessens M, Rouse M, et al.
Ann Neurol
. 2022 Nov;
93(1):142-154.
PMID: 36321699
Objective: Synaptic loss is an early feature of neurodegenerative disease models, and is severe in post mortem clinical studies, including frontotemporal dementia. Positron emission tomography (PET) with radiotracers that bind...